All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

News

Article

November 2, 2018

London-based Pharma Company Charged with Offences Related to Baby Deaths

Author(s):

Pharmaceutical Technology Editors

A London-based pharmaceutical company has been charged with offences relating to the nature and quality of medicinal product used for parenteral nutrition in babies.

A pharmaceutical company based in London, UK, ITH Pharma, has been charged with seven counts of ‘supplying a medicinal product not of the nature or quality specified in the prescription on May 27, 2014’, according to a statement from the Metropolitan Police on Oct. 31, 2018.

Additionally, the police have stated that the company has also been charged with ‘failing to take all reasonably practicable steps to ensure that patients were not infected by contaminants, in breach of the Health and Safety at Work Act’. The charges relate to offences that occurred between Aug. 1, 2009 and Jun. 1, 2014.

ITH Pharma, which specialises in the provision of aseptic compounding services for therapeutic areas, particularly parenteral nutrition, chemotherapy, and CIVAS, has responded to the charges, indicating its disappointment. It stated on its website, "As founders of ITH we have every sympathy for all the families affected, regardless of the cause. However, we are disappointed by the decision to charge the company and will vigorously defend this case. It would not be appropriate to comment further at this stage."

In a four-year long case, the Metropolitan Police have been investigating the deaths of three babies and 20 instances where babies required treatment as a result of contracting septicaemia following administration of a feeding drip in a neonatal setting.

Since it was founded in 2008, ITH Pharma has manufactured more than a million components for total parenteral nutrition and reported that it is the only commercial supplier of this sort of solution to the National Health Service. It specified on its website, "ITH imposes rigorous environmental monitoring on its manufacturing process. The company has always had a strong relationship with the [Medicines and Healthcare products Regulatory Agency] and continues to receive exemplary ratings for quality and safety."

Representatives from the company are due to appear at Westminster Magistrates’ Court on Dec. 17, 2018.

Sources: The Metropolitan Police and ITH Pharma

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Related Content
Advertisement
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 16th 2025

In Europe, the Use of Titanium Dioxide in Drugs Will Continue

Susan Haigney
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 16th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 16th 2025

FDA Commissioner Applauds Florida Restriction on 7-OH Opioids

Susan Haigney
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 16th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
Coronavirus 2019-nCov novel coronavirus concept resposible for asian flu outbreak and coronaviruses influenza as dangerous flu strain cases as a pandemic. The virus is made up of purple pills. | Image Credit: © lunarts_studio - stock.adobe.com
August 16th 2025

BARDA Pulls Plug on Vaxart Oral COVID Vaccine Trial After mRNA Rollback

Patrick Lavery
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 16th 2025

Nxera’s New GLP-1 and GPCR-Targeted Drug Programs Aim to Advance Obesity and Metabolic Disorder Therapies

Feliza Mirasol
Related Content
Advertisement
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 16th 2025

In Europe, the Use of Titanium Dioxide in Drugs Will Continue

Susan Haigney
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 16th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 16th 2025

FDA Commissioner Applauds Florida Restriction on 7-OH Opioids

Susan Haigney
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 16th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
Coronavirus 2019-nCov novel coronavirus concept resposible for asian flu outbreak and coronaviruses influenza as dangerous flu strain cases as a pandemic. The virus is made up of purple pills. | Image Credit: © lunarts_studio - stock.adobe.com
August 16th 2025

BARDA Pulls Plug on Vaxart Oral COVID Vaccine Trial After mRNA Rollback

Patrick Lavery
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 16th 2025

Nxera’s New GLP-1 and GPCR-Targeted Drug Programs Aim to Advance Obesity and Metabolic Disorder Therapies

Feliza Mirasol
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.